Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis Inc. reports biotechnology developments centered on emavusertib (CA-4948), an orally available small-molecule IRAK4 and FLT3 inhibitor. Company updates focus on oncology programs in lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia, including clinical data presentations, combination approaches with BTK inhibitors, and studies involving venetoclax and azacitidine.
Recurring Curis news also covers quarterly financial and operating results, conference-call updates, capital actions such as private placements, and security-structure matters involving preferred stock and warrants. The company’s public updates combine clinical-program progress with financing, governance and operating disclosures typical of a development-stage biotechnology issuer.
Curis (NASDAQ:CRIS) reported first quarter 2026 results and a business update focused on emavusertib (CA-4948).
- Q1 2026 net loss was $24.2M with no revenue after the Erivedge royalty sale.
- R&D expenses fell to $6.4M, while G&A rose to $5.1M.
- Other expense increased to $12.7M, mainly from warrant liability changes tied to the January 2026 PIPE financing.
- Cash and equivalents totaled $15.0M with about 40M shares outstanding.
- The January 2026 PIPE provides up to $80.8M gross proceeds via initial funding and three warrant series at $0.75 per share.
- Curis expects its cash plus potential $20.2M Series B warrant proceeds to fund operations into the second half of 2027.
- Key trials include Phase 1/2 TakeAim Lymphoma in PCNSL and Phase 2 TakeAim CLL with BTK inhibitors, plus early solid tumor data showing manageable toxicity and encouraging preliminary signals.
Curis (NASDAQ: CRIS) will report first quarter 2026 financial and operating results on May 12, 2026 at 4:00 p.m. ET and will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.
Dial-in numbers and a live audio webcast are available; a replay will be posted at www.curis.com.
Curis (NASDAQ: CRIS) reported Q4 2025 results and a business update on March 19, 2026. Key highlights include Q4 net income of $19.4M and FY 2025 net loss of $7.6M, a $27.2M non-cash gain from extinguishing a royalty liability, and a PIPE financing structure providing up to $80.8M in potential proceeds.
Clinical updates: encouraging emavusertib combo signals in PCNSL (100% ORR in 5 BTKi-naïve patients; 37% ORR in BTKi-experienced) and AML MRD conversions (5 of 8). Emavusertib holds orphan designation in PCNSL from FDA and EMA. Cash was $5.1M with guidance to fund operations into H2 2027 assuming expected warrant proceeds.
Curis (NASDAQ: CRIS) will report fourth quarter 2025 financial and operating results on Thursday, March 19, 2026 at 4:00 p.m. ET.
Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET; dial-in numbers and a live audio webcast will be available via the company website, with a replay posted at www.curis.com.
Curis (NASDAQ: CRIS) announced the closing of a private placement (PIPE) raising up to $80.8 million in gross proceeds, with initial gross proceeds of approximately $20.2 million to the company, before placement agent fees and offering expenses. The PIPE was led by Nantahala Capital, Stonepine Capital Management, Pointillist Partners, and The Red Hook Fund, and included participation from other new and existing institutional investors as well as members of Curis' management team and board. Laidlaw & Company (UK) Ltd. acted as sole placement agent.
Curis (NASDAQ: CRIS) entered a securities purchase agreement for a private placement (PIPE) expected to raise up to $80.8 million in gross proceeds, including initial gross proceeds of approximately $20.2 million, before placement agent fees and offering expenses.
The financing sells 20,195 shares of Series B convertible preferred stock plus Series A, B and C warrants (each to purchase 26,926,675 shares of common stock or pre-funded equivalents). Each Security is priced at $1,000 and the Warrants have an $0.75 exercise price. Certain company insiders are participating.
Closing is expected on or about January 8, 2026, subject to customary conditions; Series B preferred conversion and Warrant exercisability require stockholder approval and registration rights were agreed for resale registration.
Curis (NASDAQ: CRIS) posted updated clinical data from its frontline Acute Myeloid Leukemia triplet study (CA-4948-104) presented at the 67th ASH Annual Meeting on December 9, 2025. The study adds emavusertib (ema) to venetoclax plus azacitidine in AML patients who were in complete remission but remained MRD-positive.
As of October 12, 2025, 5 of 8 patients (62.5%) achieved undetectable MRD (uMRD), up from 4 of 8 (50%) reported as of July 2, 2025. The company reported no change in safety profile across the updated dataset. The first two cohorts tested ema dosing for 7 or 14 days per 28-day cycle.
Curis (NASDAQ: CRIS) will present clinical and preclinical data on emavusertib (CA-4948), an oral IRAK4 inhibitor, at the 30th Annual Society for Neuro‑Oncology (SNO) Meeting on November 19–23, 2025.
Key presentations: poster and rapid oral presentations on Nov 21–22, 2025 reporting emavusertib plus BTKi clinical data in Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL) by Dr. Christian Grommes, Dr. Lakshmi Nayak and Cecilia Merrigan; and an oral talk on Nov 23, 2025 by Christina von Roemeling on targeting Myddosome signaling in melanoma brain metastases. Times listed are local ET and HT for each session.
Curis (NASDAQ: CRIS) reported third-quarter 2025 results and clinical progress on Nov 6, 2025. The company posted a Q3 net loss of $7.7M ($0.49/share) vs $10.1M a year earlier and revenues of $3.2M. R&D expense fell to $6.4M in Q3. Cash and cash equivalents were $9.1M at Sept 30, 2025, with a runway into Q1 2026; ~12.7M shares outstanding. Operationally, Curis continues enrollment in PCNSL TakeAim (seeking accelerated US/EU filings), filed a Phase 2 CLL protocol (first patient late Q4/early Q1), reported AML triplet MRD data (50% MRD conversion, data cut Jul 2, 2025), and holds orphan designation in PCNSL.
Curis (NASDAQ: CRIS) will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025 at 4:00 p.m. ET. Management will host a conference call and simultaneous webcast the same day at 4:30 p.m. ET.
Participants can join by dialing (800) 836-8184 (U.S.) or (646) 357-8785 (international), via the live audio webcast linked from the company's events & presentations page, and a replay will be available at www.curis.com.